English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/59474
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: A step forward in the standardization of clinical immunophenotyping

AuthorsCosta, Elaine S.; Pedreira, C. E.; Barrena, Susana; Lécrevisse, Quentin; Flores-Montero, Juan; Quijano, Sandra; Almeida, Julia ; Orfao, Alberto
Issue Date2010
PublisherNature Publishing Group
CitationLeukemia 24: 1927-1933 (2010)
AbstractImmunophenotypic characterization of B-cell chronic lymphoproliferative disorders (B-CLPD) is becoming increasingly complex due to usage of progressively larger panels of reagents and a high number of World Health Organization (WHO) entities. Typically, data analysis is performed separately for each stained aliquot of a sample; subsequently, an expert interprets the overall immunophenotypic profile (IP) of neoplastic B-cells and assigns it to specific diagnostic categories. We constructed a principal component analysis (PCA)-based tool to guide immunophenotypic classification of B-CLPD. Three reference groups of immunophenotypic data filesB-cell chronic lymphocytic leukemias (B-CLL; n10), mantle cell (MCL; n10) and follicular lymphomas (FL; n10)were built. Subsequently, each of the 175 cases studied was evaluated and assigned to either one of the three reference groups or to none of them (other B-CLPD). Most cases (89%) were correctly assigned to their corresponding WHO diagnostic group with overall positive and negative predictive values of 89 and 96%, respectively. The efficiency of the PCA-based approach was particularly high among typical B-CLL, MCL and FL vs other B-CLPD cases. In summary, PCA-guided immunophenotypic classification of B-CLPD is a promising tool for standardized interpretation of tumor IP, their classification into well-defined entities and comprehensive evaluation of antibody panels. © 2010 Macmillan Publishers Limited All rights reserved.
Description7 páginas, 1 figura, 2 tablas.-- This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License.-- et al.
URIhttp://hdl.handle.net/10261/59474
DOI10.1038/leu.2010.160
Identifiersdoi: 10.1038/leu.2010.160
issn: 0887-6924
e-issn: 1476-5551
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Automated pattern-guided.pdf378,77 kBAdobe PDFThumbnail
View/Open
Show full item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.